🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. TALEN

    The First People's Hospital of Lianyungang

    Human Papillomavirus-Related Malignant Neoplasm

    phase 1 mab active

    1 trial

  2. TQB2101 for Injection

    Nanjing Zenshine Pharmaceuticals

    Advanced Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  3. TQB2825 Injection (Subcutaneous Injection)

    Shanghai University of Traditional Chinese Medicine

    CD20-positive Hematological Malignancies

    phase 1 small molecule active

    1 trial

  4. TV-46046 - 400 mg/mL

    Teva Pharma GmbH

    Pregnancy

    phase 1 small molecule completed

    1 trial

  5. TVB-2640

    Sagimet Biosciences

    Solid Malignant Tumor

    phase 1 small molecule completed

    1 trial

  6. ThisCART22 cells injection

    The First People's Hospital of Lianyungang

    B Cell Malignancy

    phase 1 mab active

    1 trial

  7. Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)

    Disc Medicine

    Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.

    phase 1 other active

    1 trial

  8. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  9. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  10. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  11. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Relapsed or Refractory Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  12. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

  13. VIR-5525

    Vir Biotechnology

    Solid Tumor Malignancies

    phase 1 small molecule active

    1 trial

  14. WX-UK1 in combination with Capecitabine

    United Therapeutics Europe Ltd

    Advanced Malignancies

    phase 1 small molecule completed

    1 trial

  15. YMN101

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 mab active

    1 trial

  16. [14C]-etrumadenant

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    1 trial

  17. [F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 1 small molecule completed

    1 trial

  18. alisertib

    Takeda

    Advanced Malignancies

    phase 1 small molecule completed

    2 trials

  19. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial

  20. bendamustine

    Teva Pharma GmbH

    Malignancy

    phase 1 small molecule completed

    1 trial

  21. cyclophosphamide

    Evidence Based Cataract Study Group

    Malignant Pleural Mesothelioma (MPM)

    phase 1 small molecule active

    1 trial

  22. domestic polysaccharide superparamagnetic iron oxide nanoparticle

    The First People's Hospital of Lianyungang

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  23. etrumadenant

    Arcus Biosciences

    GastroEsophageal Cancer

    phase 1 small molecule completed

    1 trial

  24. intraconazole

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources